Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Jesus Gomez-Navarro"'
Autor:
F Javier Ibarrondo, Otto O Yang, Thinle Chodon, Earl Avramis, Yohan Lee, Hooman Sazegar, Jason Jalil, Bartosz Chmielowski, Richard C Koya, Ingrid Schmid, Jesus Gomez-Navarro, Beth D Jamieson, Antoni Ribas, Begoña Comin-Anduix
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76829 (2013)
A significant barrier to effective immune clearance of cancer is loss of antitumor cytotoxic T cell activity. Antibodies to block pro-apoptotic/downmodulatory signals to T cells are currently being tested. Because invariant natural killer T cells (iN
Externí odkaz:
https://doaj.org/article/86bbe706996e4d22b7abc83500cf3d2b
Autor:
Begoña Comin-Anduix, Hooman Sazegar, Thinle Chodon, Douglas Matsunaga, Jason Jalil, Erika von Euw, Helena Escuin-Ordinas, Robert Balderas, Bartosz Chmielowski, Jesus Gomez-Navarro, Richard C Koya, Antoni Ribas
Publikováno v:
PLoS ONE, Vol 5, Iss 9, p e12711 (2010)
The effects on cell signalling networks upon blockade of cytotoxic T lymphocyte-associated antigen-4 (CTLA4) using the monoclonal antibody tremelimumab were studied in peripheral blood mononuclear cell (PBMC) samples from patients with metastatic mel
Externí odkaz:
https://doaj.org/article/d7329642d3d84e15b0ee700bc793b3d5
Autor:
Antoni Ribas, Alistair J. Cochran, John A. Glaspy, Jesus Gomez-Navarro, Arturo Villanueva, Elizabeth Seja, Hooman Sazegar, Stephen Mok, Richard C. Koya, Bartosz Chmielowski, James S. Economou, Jason Jalil, Rong Rong Huang
Supplementary Figure 2 from CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14d5147d23c240315ca5b85954401416
https://doi.org/10.1158/1078-0432.22441083
https://doi.org/10.1158/1078-0432.22441083
Autor:
Jesus Gomez-Navarro, James S. Economou, Ena Wang, Francesco M. Marincola, Liu Hui, John A. Glaspy, Alistair J. Cochran, Bradley R. Straatsma, Denise K. Oseguera, Arturo Villanueva, Elizabeth Seja, Maria Teresa Ochoa, Tara A. McCannel, Pilar de la Rocha, Jason Jalil, Bartosz Chmielowski, Begoña Comin-Anduix, Antoni Ribas
Supplementary Table S1 from Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c775c5786b020ca538cdf9317cff78e
https://doi.org/10.1158/1078-0432.22439974.v1
https://doi.org/10.1158/1078-0432.22439974.v1
Autor:
Antoni Ribas, Alistair J. Cochran, John A. Glaspy, Jesus Gomez-Navarro, Arturo Villanueva, Elizabeth Seja, Hooman Sazegar, Stephen Mok, Richard C. Koya, Bartosz Chmielowski, James S. Economou, Jason Jalil, Rong Rong Huang
Background: CTLA4 blocking monoclonal antibodies provide durable clinical benefit in a subset of patients with advanced melanoma mediated by intratumoral lymphocytic infiltrates. A key question is defining whether the intratumoral infiltration (ITI)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bf487e6eb2773ad6da925d36d9f948f
https://doi.org/10.1158/1078-0432.c.6518253.v1
https://doi.org/10.1158/1078-0432.c.6518253.v1
Autor:
Alistair J. Cochran, Jesus Gomez-Navarro, John A. Glaspy, Itsushi Peter Shintaku, Vivian B. Dissette, Jason Jalil, Lilah F. Morris, Pilar de la Rocha, Timothy R. Donahue, James S. Economou, Begoña Comin-Anduix, Antoni Ribas
Purpose: CTL-associated antigen 4 (CTLA4)-blocking monoclonal antibodies induce long-term regression of metastatic melanoma in some patients, but the exact mechanism is unknown. In this study, biopsies of selected accessible tumor lesions from patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37e7d895d6b297e5b8054d157527d94a
https://doi.org/10.1158/1078-0432.c.6516898.v1
https://doi.org/10.1158/1078-0432.c.6516898.v1
Autor:
Alistair J. Cochran, Jesus Gomez-Navarro, John A. Glaspy, Itsushi Peter Shintaku, Vivian B. Dissette, Jason Jalil, Lilah F. Morris, Pilar de la Rocha, Timothy R. Donahue, James S. Economou, Begoña Comin-Anduix, Antoni Ribas
Supplementary Figures S1-S2 from Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::339ce47d5b582f32b1f6f69a2204138e
https://doi.org/10.1158/1078-0432.22439428
https://doi.org/10.1158/1078-0432.22439428
Autor:
Antoni Ribas, Alistair J. Cochran, John A. Glaspy, Jesus Gomez-Navarro, Arturo Villanueva, Elizabeth Seja, Hooman Sazegar, Stephen Mok, Richard C. Koya, Bartosz Chmielowski, James S. Economou, Jason Jalil, Rong Rong Huang
Supplementary Figure 1 from CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08d5480df2a9182c047a51601e95a6da
https://doi.org/10.1158/1078-0432.22441086
https://doi.org/10.1158/1078-0432.22441086
Autor:
Jesus Gomez-Navarro, James S. Economou, Ena Wang, Francesco M. Marincola, Liu Hui, John A. Glaspy, Alistair J. Cochran, Bradley R. Straatsma, Denise K. Oseguera, Arturo Villanueva, Elizabeth Seja, Maria Teresa Ochoa, Tara A. McCannel, Pilar de la Rocha, Jason Jalil, Bartosz Chmielowski, Begoña Comin-Anduix, Antoni Ribas
Purpose: Tumor antigen–loaded dendritic cells (DC) are believed to activate antitumor immunity by stimulating T cells, and CTL-associated antigen 4 (CTLA4)–blocking antibodies should release a key negative regulatory pathway on T cells. The combi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::571beeec5ed7803a0b00b4530f69968b
https://doi.org/10.1158/1078-0432.c.6517354.v1
https://doi.org/10.1158/1078-0432.c.6517354.v1
Autor:
Karthik Venkatakrishnan, Christopher J. Endres, Ashish Suri, Graham P. Collins, Jesus Gomez-Navarro, Diane R. Mould, Gregory Song
Publikováno v:
Clinical Pharmacology and Therapeutics
The efficacy of the CD30-directed antibody-drug conjugate (ADC) brentuximab vedotin was established in combination with chemotherapy as frontline treatment for advanced classical Hodgkin's lymphoma in the randomized phase III ECHELON-1 study. Populat